Zooming in on SARS-CoV-2 Replication to Develop Antiviral Therapies
Antiviral drugs that slow SARS-CoV-2 replication in patient cells are critical for curbing the pandemic. For RNA viruses such as SARS-CoV-2, genome duplication hinges on RNA polymerase, making the enzyme an ideal therapeutic target for drug development. Researchers now study the enzyme’s function to design inhibitors, such as nucleoside analogs, that specifically block viral replication.
Watch this webinar to discover:
- How scientists study RNA polymerase activity with the Typhoon™ laser-scanner platform
- What makes SARS-CoV-2's RNA polymerase the ideal target for drug development
- Mutagenic nucleotide analogs that stall SARS-CoV-2 virus replication
Speakers
Barbara Selisko, PhD
Research Associate, Aix Marseille University
Ashleigh Shannon, PhD
Postdoctoral Researcher, Aix Marseille University
